7,650.00

+36.00

+0.47%

52,111.00

+193.00

+0.37%

28,798.50

+264.50

+0.93%

Russell 2000 Futures

2,839.10

+17.80

+0.63%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,911.80

+12.90

+0.33%

78,379.43

+715.07

+0.92%

Crude Oil Dec 26

100.77

-3.35

-3.22%

US Private Equity

10,850.63

-82.20

-0.75%

KSE - Delayed Quote KRW

GC Biopharma Corp. (006280.KS)

133,900.00 +3,700.00 (+2.84%)

As of 11:53:01 AM GMT+9. Market Open.

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Stocktwits 2d ago

BMRN

006280.KS
+2.84%
128940.KS
GC Biopharma to Present Expanded IVIG Aggregation Analysis and Additional Phase 3 ALYGLO® Safety Analysis at IgNS 2026

Business Wire 19d ago

006280.KS
+2.84%
Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU

GlobeNewswire 2mo ago

006280.KS
+2.84%
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

PR Newswire 3d ago

BMRN

006280.KS
+2.84%
128940.KS
Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines

GlobeNewswire 17d ago

006280.KS
+2.84%
GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan

PR Newswire 2mo ago

006280.KS
+2.84%

Mobilize your Website

View Site in Mobile | Classic

Share by: